United States


XOMA.OQ on NASDAQ Stock Exchange Global Market

9:56am EST
Change (% chg)

$-0.04 (-0.72%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for XOMA.OQ


XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA... (more)


Beta: 3.66
Market Cap(Mil.): $33.44
Shares Outstanding(Mil.): 6.05
Dividend: --
Yield (%): --


  XOMA.OQ Industry Sector
P/E (TTM): -- 41.20 30.65
EPS (TTM): -1.73 -- --
ROI: -99.20 -0.59 15.23
ROE: -- -1.31 16.56

BRIEF-Xoma Q3 loss $2.08/shr

* Xoma reports third quarter 2016 achievements and financial results

Nov 09 2016

BRIEF-XOMA says regulatory body in Germany approves plan to conduct repeat-dose clinical study in congenital hyperinsulinism patients over age of 12

* Xoma announces significant step toward initiating pediatric phase 2 clinical study for XOMA 358 in children with congenital hyperinsulinism

Oct 19 2016

BRIEF-Xoma announces reverse stock split

* Board of directors then determined that split would be at a ratio of 1-for-20

Oct 14 2016

BRIEF-XOMA provides update from ongoing phase 2 XOMA 358 clinical studies

* XOMA provides update from ongoing phase 2 XOMA 358 clinical studies

Sep 15 2016

BRIEF-Xoma wins EU "orphan drug" status for hyperinsulinism drug

* Xoma 358 is in phase 2 development for chi with clinical sites in united states and european union (eu) actively enrolling patients

Jul 20 2016


  Price Chg
Albireo Pharma Inc (ALBO.OQ) $24.29 -0.41

Earnings vs. Estimates